NYSE:CVS

CVS Health Corp (CVS)

97.10
+0.02 (0.02%)
as of Jun 9, 2026, 3:24:57 pm Market Open.
411 watching
0
Investor Insights
star iconJun 9, 2026, 12:00 am

This summary was created by AI, based on 9 opinions in the last 12 months.

CVS Health Corp has recently demonstrated strong performance, beating earnings and revenue expectations, which has led to an increase in share value. Analysts highlight the company's strategic shift towards managed care, noting significant revenue growth in their health service division and pharmacy benefits. Despite potential concerns regarding the retail pharmacy's performance, the overall outlook appears promising as the management team effectively steers the company's turnaround. While some experts caution about the visible challenges and competition, they acknowledge that CVS's valuation is appealing compared to its peers in the healthcare sector, suggesting that the company may still have significant room for growth as it reinvents itself.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
UNH
DON'T BUY

Benefited during Covid, now fallen off. Diversified. Attractive multiple. Keeps acquiring to broaden its offerings. Not sure what catalyst is to get valuation multiple up. She owns other companies in healthcare.

HOLD

Healthcare sector has been challenged, but growth rates will be robust over many years. Vertically integrated powerhouse. Very high free cashflow yield, in the low teens. Trades at 9x earnings. Unloved, but patience will pay off.

BUY ON WEAKNESS

It's been frustrating this year, down 25% probably due to the Oak Street and Signify deals earlier this year. CVS lowered guidance regarding the cost of these deals, but these will be accretive long term. He likes CVS long term. You can buy it now.

WAIT

It has been in free fall in recent months. It is not just a drugstore anymore but is venturing into primary care and health insurance. Its profit margins could be less because many surgeries postponed during the pandemic are now being done. Wait for it to settle.

BUY

Only about 1/3 is health insurance. This week's announcement of more elective surgeries will impact them less. Vertically integrated. Unique, defensive exposure for a Canadian investor. 8x PE, massive free cashflow.

HOLD

Healthcare as not performed well this year.
Technology attracting lots of investor money in the short term. 
Long term, demand for healthcare is strong.
Recent M&A and company re-organization has negatively impacted share price.
Current share price presenting value - however waiting to see how company stabilizes.


BUY

Excellent company for long term investors.
Healthcare demand very strong.
Boomers will require lots of health care going forward.
Recent M&A not a concern.
Diverse business with many revenue streams.

BUY ON WEAKNESS

Health care business a very good long term sector.
Strong business with defensive characteristics.
Excellent business fundamentals.
Management very strong with deep experience.
Sees a lot of potential for business.

PARTIAL SELL

A long-term holding for him. Had a great 2022, but a disappointing 2023. He reduced his holding last September and March due to valuation and higher costs. It still trades at a premium within healthcare. 

DON'T BUY

Very low multiple, and has for many years. It's diversifying vertically. It never seemed to come through with earnings, so she decided to focus on more concentrated plays in healthcare such as pharma or medical devices.

PAST TOP PICK
(A Top Pick May 03/22, Down 28%)

Has great expectations for company, will continue to hold.
Trading ~8x earnings. 
Owns many legacy assets and brands.
~10,000 storefronts for strong retail business.
Good long term hold. 
Cash flow juggernaut with excellent margins. 
Good management team.

BUY

Makes a lot of sense for a long-term hold. Beat numbers. Poor guidance going forward. Health business, rather than just a drugstore, but this creates volatility in earnings sometimes. Focus on integrated strategy is the right approach.

DON'T BUY

It is trying to become vertically integrated in managed care, health insurance, doctors networks. It is attempting to be a turn-around story so wait until it executes on its strategy of becoming a conglomerate. There are other companies that are best in class already

PAST TOP PICK
(A Top Pick May 05/22, Down 27%)

Acquisitions have hampered stock price. Targets keep getting pushed our further. Lowered guidance. May be support levels around this price. Trades at 8x forward earnings, well below its historical 12.5x PE. Growth remains elusive. Dividend's great at 3.5%.

STRONG BUY

He bought more CVS. Not a bad earnings report, but have extra costs coming from the Oak Street  and Signify purchases. They've been growing earnings for the past 5 years at 10% annually. Are paying down debt. Trades at 8x earnings and pays a 3.3% dividend. Great long-term hold.

Showing 76 to 90 of 464 entries